Frontiers in Psychiatry | Psychopharmacology

Original Research

Published on 13 Nov 2023

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample

in Psychopharmacology

Tor-Morten Kvam
Malin V. Uthaug
Kristoffer A. A. Andersen
Birk Berggrav Refsum
Paula Aarseth Tunstad
Lowan Han Stewart
Henrik Børsting Jacobsen
Cato Grønnerød

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1287196

3,617 views
6 citations

Editorial

Published on 06 Nov 2023

Editorial: Alternative treatments to classical antidepressants in treatment-resistant depression

in Psychopharmacology

Georgios Mikellides
Theodoros Koutsomitros
Olympia Evagorou
Nikolaos Gkouvas
Kuan-Pin Su
Panayiota Michael

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1306117

2,589 views

Original Research

Published on 03 Nov 2023

The Utah psychotropic oversight program: collaboratively addressing antipsychotic use within youth in foster care without prior authorization

in Psychopharmacology

Eric T. Monson
Sachi Shastri
Danli Chen
Stacy L. Madden
Brooks R. Keeshin

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1271165

1,747 views

Original Research

Published on 02 Nov 2023

Home-administered transcranial direct current stimulation with asynchronous remote supervision in the treatment of depression: feasibility, tolerability, and clinical effectiveness

in Psychopharmacology

Theodoros Koutsomitros
Sandra A. Schwarz
Kenneth T. van der Zee
Teresa Schuhmann
Alexander T. Sack

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1206805

4,068 views
1 citation

Case Report

Published on 25 Oct 2023

Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study

in Psychopharmacology

Steffen Reissmann
Matthias Hartmann
Andreas Kist
Matthias E. Liechti
Kurt Stocker

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1197697

2,796 views

Editorial

Published on 19 Oct 2023

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges

in Psychopharmacology

Brian S. Barnett
Anahita Bassir Nia
Nathan B. Sackett
Jeremy Weleff

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1305478

2,626 views

Case Report

Published on 10 Oct 2023

Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report

in Psychopharmacology

Jianhong Wu
Jiao Yu
Kankan Qu
Jiajun Yin
Chunming Zhu
Xiaowei Liu

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1257984

3,740 views
3 citations

Original Research

Published on 06 Oct 2023

Paliperidone long-acting injection in the treatment of an adolescent with schizophrenia with fluctuating mental symptoms during menstrual period: a case report

in Psychopharmacology

Feng Wang
Juan Chen
Linglin Guo
Zhixiong Li
Zhe Li

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1276983

2,804 views
1 citation

Original Research

Published on 03 Oct 2023

Dose-dependent QTc interval prolongation under haloperidol and pipamperone in the management of delirium in a naturalistic setting

in Psychopharmacology

Philipp Bohny
Soenke Boettger
Josef Jenewein

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1257755

2,695 views
3 citations

Systematic Review

Published on 22 Sep 2023

Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis

in Psychopharmacology

Kenichi Kimura
Hisashi Narita
Hissei Imai
Hisashi Akiyama
Shuhei Ishikawa
Ryo Sawagashira
Tomoyuki Isoyama
Mariko Nohara
Michiyo Kawamura
Yukari Kono

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1248397

12,677 views
2 citations

Perspective

Published on 20 Sep 2023

Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the “high-risk” addiction patient

in Psychopharmacology

Taylor Black

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1159843

3,365 views
1 citation

Original Research

Published on 19 Sep 2023

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

in Psychopharmacology

Sandeep M. Nayak
Hillary Jackson
Nathan D. Sepeda
David S. Mathai
Sara So
Abigail Yaffe
Hadi Zaki
Trey J. Brasher
Matthew X. Lowe
Del R. P. Jolly

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1199642

45,161 views
30 citations

Methods

Published on 19 Sep 2023

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression

in Psychopharmacology

Nicolas Garel
Jessica Drury
Julien Thibault Lévesque
Nathalie Goyette
Alexandre Lehmann
Karl Looper
David Erritzoe
Shannon Dames
Gustavo Turecki
Soham Rej

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1268832

13,556 views
6 citations

Original Research

Published on 15 Sep 2023

Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the COVID-19 pandemic

in Psychopharmacology

Botao Ma
Hongzhen Fan
Siyuan Qi
Fude Yang
Huimei An

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1256264

1,958 views

Original Research

Published on 30 Aug 2023

Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review

in Psychopharmacology

Emily Whinkin
Therry Rose J. Eparwa
Michelle C. Julseth
Andrea Schneider
Sunil K. Aggarwal

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1160442

3,367 views

Editorial

Published on 21 Aug 2023

Editorial: Community series in novel antipsychotics within and beyond clinical trials: symptom-based treatment of psychiatric disorders with D3-D2 partial agonists, volume II

in Psychopharmacology

Peter Falkai
Zsófia Borbála Dombi

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1266566

1,237 views

Navigation group

Articles

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample

Editorial: Alternative treatments to classical antidepressants in treatment-resistant depression

The Utah psychotropic oversight program: collaboratively addressing antipsychotic use within youth in foster care without prior authorization

Home-administered transcranial direct current stimulation with asynchronous remote supervision in the treatment of depression: feasibility, tolerability, and clinical effectiveness

Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges

Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report

Paliperidone long-acting injection in the treatment of an adolescent with schizophrenia with fluctuating mental symptoms during menstrual period: a case report

Dose-dependent QTc interval prolongation under haloperidol and pipamperone in the management of delirium in a naturalistic setting

Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis

Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the “high-risk” addiction patient

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression

Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the COVID-19 pandemic

Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review

Editorial: Community series in novel antipsychotics within and beyond clinical trials: symptom-based treatment of psychiatric disorders with D3-D2 partial agonists, volume II